Cargando…
Pharmacologic Inhibition of CXCL10 in Combination with Anti-malarial Therapy Eliminates Mortality Associated with Murine Model of Cerebral Malaria
Despite appropriate anti-malarial treatment, cerebral malaria (CM)-associated mortalities remain as high as 30%. Thus, adjunctive therapies are urgently needed to prevent or reduce such mortalities. Overproduction of CXCL10 in a subset of CM patients has been shown to be tightly associated with fata...
Autores principales: | Wilson, Nana O., Solomon, Wesley, Anderson, Leonard, Patrickson, John, Pitts, Sidney, Bond, Vincent, Liu, Mingli, Stiles, Jonathan K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3618178/ https://www.ncbi.nlm.nih.gov/pubmed/23630573 http://dx.doi.org/10.1371/journal.pone.0060898 |
Ejemplares similares
-
Neuregulin-1 attenuates mortality associated with experimental cerebral malaria
por: Solomon, Wesley, et al.
Publicado: (2014) -
Heme Mediated STAT3 Activation in Severe Malaria
por: Liu, Mingli, et al.
Publicado: (2012) -
CXCL10 Gene Promoter Polymorphism -1447A>G Correlates with Plasma CXCL10 Levels and is Associated with Male Susceptibility to Cerebral Malaria
por: Wilson, Nana, et al.
Publicado: (2013) -
CXCL4 and CXCL10 Predict Risk of Fatal Cerebral Malaria
por: Wilson, Nana O., et al.
Publicado: (2011) -
Neuregulin-1 attenuates experimental cerebral malaria (ECM) pathogenesis by regulating ErbB4/AKT/STAT3 signaling
por: Liu, Mingli, et al.
Publicado: (2018)